Tenax Therapeutics is trading at $1.71 (-5.00%), with no new company announcement clearly explaining the August 17, 2026 decline.
- The stock remains highly volatile after the August 10 Phase 3 LEVEL trial failure, which missed primary and key secondary endpoints.
- August 17 coverage reported a pending investor investigation but did not establish it as the cause of today’s move.
- Broader markets are modestly lower, though not enough to clearly explain this decline.